National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), Shanghai, People's Republic of China; NHC Key Laboratory of Parasite and Vector Biology, Shanghai, People's Republic of China; WHO Collaborating Centre for Tropical Diseases, Shanghai, People's Republic of China; National Center for International Research on Tropical Diseases, Shanghai, People's Republic of China.
Fudan University School of Public Health, Shanghai, People's Republic of China; Key Laboratory of Public Health Safety, Fudan University, Ministry of Education, Shanghai, People's Republic of China; Fudan University Center for Tropical Disease Research, Shanghai, People's Republic of China.
Int J Infect Dis. 2023 May;130:147-152. doi: 10.1016/j.ijid.2023.03.011. Epub 2023 Mar 11.
In this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence on severity of infection and some other variables.
A systemic review with the search terms: "COVID-19" or "SARS-CoV-2" and "autoantibodies" or "autoantibody" and "IFN" or "interferon" for the period 20 December 2019 to 15 August 2022 was carried out using PubMed, Embase, Cochrane, and Web of Science. R 4.2.1 software was used for meta-analysis of the published results. Pooled risk ratios and 95% confidence intervals (CIs) were calculated.
We identified eight studies involving 7729 patients, of whom 5097 (66%) had severe COVID-19 and 2632 (34%) had mild or moderate symptoms. The positive rate of anti-type-I-IFN-autoantibodies in the total dataset was 5% (95% CI, 3-8%), but reached 10% (95% CI, 7-14%) in those with severe infection. The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%). The overall prevalence in male patients was 5% (95% CI, 4-6%), and in female patients 2% (95% CI, 1-3%).
Severe COVID-19 is associated with high rates of autoantibodies against type-I-IFN and more so in male than female patients.
本研究旨在研究 COVID-19 患者中针对 I 型干扰素（IFN）的自身抗体的发生率，并分析其对感染严重程度和其他一些变量的依赖性。
使用 PubMed、Embase、Cochrane 和 Web of Science 数据库，以“COVID-19”或“SARS-CoV-2”和“自身抗体”或“自身抗体”和“IFN”或“干扰素”为检索词，对 2019 年 12 月 20 日至 2022 年 8 月 15 日期间的文献进行系统回顾。使用 R 4.2.1 软件对已发表结果进行荟萃分析。计算合并的风险比和 95%置信区间（CI）。
我们确定了八项涉及 7729 例患者的研究，其中 5097 例（66%）患有严重 COVID-19，2632 例（34%）患有轻度或中度症状。总数据集自身抗体阳性率为 5%（95%CI，3-8%），但在严重感染患者中达到 10%（95%CI，7-14%）。最常见的亚型是抗 IFN-α（89%）和抗 IFN-ω（77%）。男性患者的总体患病率为 5%（95%CI，4-6%），女性患者为 2%（95%CI，1-3%）。
严重 COVID-19 与针对 I 型 IFN 的自身抗体的高发生率相关，且男性患者比女性患者更为显著。
Zotero 插件
